[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Xeris Biopharma Inc LSE:0A8E London Ordinary Share XERIS BIOPHARMA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.00 -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Morgan Stanley Smith Barney LLC Form 8.3 - XERIS PHARMACEUTICALS INC

01/10/2021 10:13am

UK Regulatory (RNS & others)


TIDM0A8E

RNS Number : 7321N

Morgan Stanley Smith Barney LLC

01 October 2021

   FORM   8.3 
   IRISH  TAKEOVER   PANEL 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH  TAKEOVER   PANEL ACT,  1997,  TAKEOVER  RULES, 2013 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY   INFORMATION 
 
 Name of person dealing      Morgan Stanley Smith Barney 
  (Note 1)                    LLC 
 Company dealt in            XERIS PHARMACEUTICALS INC 
                             =========================== 
 Class of relevant security  $0.001 COMMON STOCK 
  to which the dealings 
  being disclosed relate 
  (Note 2) 
                             =========================== 
 Date of dealing             30 September 2021 
                             =========================== 
 
   2.       INTERESTS AND SHORT POSITIONS 
     (a)         Interests and short positions (following dealing) in the class of relevant security 

dealt in ( Note 3)

 
                                          Long                Short 
                              Number        (%)    Number        (%) 
                             ===========   =====  ===========   ====== 
 (1) Relevant securities       12,388      0.02        0         0.00 
                             ===========  ======  ===========  ======= 
 (2)Derivatives (other 
  than options)                   0        0.00        0         0.00 
                             ===========  ======  ===========  ======= 
 (3)Options and agreements 
  to purchase/sell                0        0.00        0         0.00 
                             ===========  ======  ===========  ======= 
 Total                         12,388      0.02        0         0.00 
                             ===========  ======  ===========  ======= 
 
 
   (b)      Interests and short positions in relevant securities of the company, other than the 

class dealt in ( Note 3 )

 
Class of relevant security:                Long                Short 
                               Number        (%)    Number        (%) 
                              ===========   =====  ===========   ====== 
 (1) Relevant securities           0        0.00        0         0.00 
                              ===========  ======  ===========  ======= 
 (2)Derivatives (other 
  than options)                    0        0.00        0         0.00 
                              ===========  ======  ===========  ======= 
 (3)Options and agreements 
  to purchase/sell                 0        0.00        0         0.00 
                              ===========  ======  ===========  ======= 
 Total                             0        0.00        0         0.00 
                              ===========  ======  ===========  ======= 
 
 
   1.       DEALINGS  (Note   4) 
   (a)      Purchases and sales 
 
 Purchase/sale         Number of relevant securities       Price per unit 
                                                            (Note 5) 
SALE            160                                   2.3850 USD 
                ====================================  =================== 
SALE            629                                   2.4500 USD 
                ====================================  =================== 
SALE            29                                    2.4720 USD 
                ====================================  =================== 
 
   (b)      Derivatives transactions (other than options transactions) 
 
 Product     Nature of transaction   Number of relevant   Price per 
  name,       (Note 6)                securities           unit 
  e.g. CFD                            (Note 7)             (Note 5) 
N/A         N/A                     N/A                  N/A 
            ======================  ===================  ========== 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing,  selling, purchasing or varying 
 
Product  Writing,      Number          Exercise  Type,       Expiry  Option money 
 name,    selling,      of securities   price     e.g.        date    paid/received 
 e.g.     purchasing,   to which                  American,           per unit 
 call     varying       the option                European            (Note 5) 
 option   etc.          relates                   etc. 
                        (Note 7) 
N/A      N/A           N/A             N/A       N/A         N/A     N/A 
         ============  ==============  ========  ==========  ======  ============== 
 
   (ii)      Exercising 
 
 Product name,             Number of securities       Exercise price 
  e.g. call option                                     per unit (Note 
                                                       5) 
N/A                 N/A                          N/A 
                    ===========================  ==================== 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
 Nature of transaction         Details       Price per unit 
  (Note 8)                                    (if applicable) 
                                              (Note 5) 
N/A                     N/A             N/A 
                        ==============  ===================== 
 
   2.       OTHER  INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

 
              Full details of any agreement, arrangement or 
               understanding between the person disclosing and 
               any other person relating to the voting rights 
               of any relevant securities under any option referred 
               to on this form or relating to the voting rights 
               or future acquisition or disposal of any relevant 
               securities to which any derivative referred to 
               on this form is referenced. If none, this should 
               be stated. 
 
   NONE 
 
   Is a Supplemental Form 8 attached?  (Note   9)                                              NO 
 
Date of disclosure            01 October 2021 
Contact name                  Craig Horsley 
                              ================ 
Telephone number              +44 141 245-7736 
                              ================ 
If a connected EFM, name      N/A 
 of offeree/offeror with 
 which connected 
                              ================ 
If a connected EFM, state     N/A 
 nature of connection (Note 
 10) 
                              ================ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEMZMGGLMZGMZG

(END) Dow Jones Newswires

October 01, 2021 05:13 ET (09:13 GMT)

1 Year Xeris Biopharma Chart

1 Year Xeris Biopharma Chart

1 Month Xeris Biopharma Chart

1 Month Xeris Biopharma Chart
ADVFN Advertorial
Your Recent History
LSE
0A8E
Xeris Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220127 06:28:34